Redefining Lung Therapy

At MimeCure, we are working to improve the lives of people living with serious long-term lung diseases such as Idiopathic Pulmonary Fibrosis (IPF) and Chronic Obstructive Pulmonary Disease (COPD). These conditions make it increasingly difficult to breathe and can have a major impact on daily life. While current treatments can slow the disease, they cannot repair the damaged lung tissue. For many patients, there are still very few options that truly change the course of their illness.

Introducing MC002

MC002 is MimeCure’s leading therapy in development. It is based on a naturally occurring protein in the body and is designed to help the lungs repair themselves. Instead of only treating symptoms, MC002 aims to support the regrowth and healing of the tiny air sacs in the lungs that are essential for breathing.

By addressing the root causes of lung damage, MC002 has the potential to slow or even change how these diseases progress. This regenerative approach offers new hope for patients with limited treatment options and could reduce the long-term burden of chronic lung disease for both patients and society.